Although it is generally believed that the beneficial effect of loop diuretics is the result of a rapid increase in diuresis, substantial evidence, from a large number of in vitro and in vivo experiments, has accumulated showing that administration of furosemide causes direct vascular effects, which probably contribute to its acute clinical effects, Several mechanisms are involved in the vascular response to loop diuretics. The role of the renin-angiotensin-aldosterone axis, prostaglandins and the direct vascular effects of loop diuretics on both the arterial and venous parts of the vasculature are discussed.
Introduction
Diuretic therapy has proved to be effective in the treatment of acute and chronic heart failure. The potent loop diuretics, furosemide and bumetanide, are frequently used in the treatment of disease states characterized by fluid and sodium retention. After intravenous administra tion of furosemide, clinical relief of symptoms often pre cedes the increase in diuresis in patients with acute heart failure, suggesting the presence of an extrarenal effect. Although it is generally believed that the beneficial effect of loop diuretics is the result of a rapid increase in diuresis, substantial evidence, from a large number of in vivo and in vitro experiments, has accumulated showing that adminis tration of furosemide causes vascular effects, which proba bly contribute to its acute clinical effects.
At first sight the reports on the vascular non-diuretic effects of furosemide seem conflicting. However, a great deal of the disparity in the results seems to be due to differences in the vascular bed studied (arterial or venous, renal or pulmonary, etc.), the species studied, the timing (acute vs. chronic effects), systemic vs. local effects, direct vs, indirect effects and differences in disease states. In this paper the literature on vascular effects of loop diuretics t (with emphasis on furosemide) is reviewed with reference to the differences in experimental protocols. Finally, some general conclusions are drawn, and suggestions for future investigations are given.
2« In vitro studies
The direct vascular effects of furosemide are difficult to study in vivo because of interfering counteracting mecha nisms which may even completely mask direct effects. In a number of in vitro studies the presence of Na+K+Cl~ co-transport activity has been demonstrated in endothelial as well as vascular smooth muscle cells [1] [2] [3] , and this observation represents a primary focus of interest with regard to the vascular effects of furosemide. However, inhibition of Na+K+Cl_ co-transport activity occurs only at high furosemide concentrations. These concentrations are reached in the renal tubule, but not in the cardio vascular system [4] . It should be emphasized that in all in vitro studies much higher concentrations were needed to induce vascular responses than in the human in vivo situation. An additional difference causing much higher concentrations of free furosemide is the absence of protein binding in the media used. 
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The in vitro studies focussing on the vascular effects of furosemide are summarized in Table 1 . In the early 1970's an inhibitory effect of furosemide on the vasoconstrictor response to norepinephrine and angiotensin II was ob served in the rat portal vein [5] . It was demonstrated that incubation with furosemide causes a membrane hyperpo larisation of 5.5 mV in the relaxed rabbit pulmonary artery [6] . Many vasodilatory agents act by hyperpolarisation of the plasma membrane and subsequent closure of voltagedependent calcium channels, so this observation is consis tent with, and possibly explains, the direct vasodilatory action of furosemide.
Furosemide appeared to have a direct vascular effect in the perfused mesenteric vascular bed of the rat [7] . In an in vitro study with arterial vascular smooth muscle in seg ments of rabbit blood vessels, furosemide (20 juig/ml) induced a small decrease in resting tension [8] ,
In the isolated rabbit central ear artery a direct relaxing effect of furosemide on isolated vessel segments was concentration-dependent (0.1 -1.0 mM furosemide) [9] . It was demonstrated that inhibition of N a+K+Cl~ co-trans port activity or hyperpolarization of the membrane was unlikely to be the sole mechanism responsible for the vasorelaxant effect of furosemide.
In an in vitro study using dogs it was demonstrated that furosemide did not have a direct effect on arterial smooth muscle, but exhibits selective venorelaxant activity [10] . The magnitude of this effect was most pronounced in the pulmonary vascular bed. Moreover, the vasorelaxant activ ity of furosemide was independent of endothelium, nitric oxide, cyclic GMP and prostanoids.
The role of the endothelium in the direct vascular effects of furosemide is still unclear. Whereas one report on an ex vivo experiment showed that the effect of furosemide on the response to sympathetic stimulation was endothelium-dependent [11] , others did not find an impor tant role for the endothelium in mediating the relaxation caused by furosemide in vitro [9] , The discrepancy be tween these results with respect to the endothelium-dependency may be caused by the different concentrations of furosemide studied and by the use of albumin-containing solutions [8] .
In vivo studies after systemic administration
During the 1970's interest increased in the vascular effects of diuretics. With the development of tools to monitor changes in haemodynamic parameters, these ef fects could be described more appropriately. In most of these studies, as discussed in the next paragraph and summarized in Table 2 , loop diuretics were administered systemically. However, it should be noted that the changes in haemodynamic parameters observed directly after ad ministration of the loop diuretic do not necessarily imply direct vasoactivity of the loop diuretic.
A study by Dikshit et al. is one of the first reports that focussed on the vascular effects of loop diuretics [12] . In 20 patients with left ventricular failure, intravenous admin istration of furosemide caused a prompt fall in left ventric ular filling pressure, which was accompanied by an in crease in venous compliance, the latter being a marker for venodilatation. These phenomena preceded an increase in urine and electrolyte output. In dogs, furosemide produced a rapid reduction in pulmonary wedge pressure and an increase in venous compliance even though the ureters were ligated [13] . These observations indicate that this venous effect may not have been the result of a decrease in plasma volume. The dissociation of diuretic and vascular effects was confirmed in a study with hypertensive pa tients: despite a fall in blood pressure, plasma volume did not change after administration of furosemide in combina tion with a high salt intake [14] . In patients with peripheral edema and mild hypertension the use of furosemide re sulted in a decrease in mean arterial pressure, cardiac output and total peripheral resistance, whereas the venous capacitance increased without change in plasma and blood volume [15] . However, the dissociation between venodilation and plasma volume is not always obvious. In patients with mild heart disease or hypertension, 80 mg i.v. furosemide caused a decrease in right atrial pressure, pul monary arterial pressure and pulmonary artery wedge pres sure (signifying increased venous compliance), together with a decrease in cardiac index within 20 min [16] . In this study, a haemoconcentration was observed as well, sug gesting that the haemodynamic effects were secondary to intravenous volume reduction through diuresis.
The relationship between haemodynamic and hormonal changes after furosemide injection and during chronic furosemide treatment was studied in patients with conges tive heart failure [17] . Cardiac output decreased signifi cantly after furosemide injection (1 m g/kg body weight), reached its nadir after 90 min and returned to baseline within 4 h. The mean pulmonary arterial pressure de creased steadily throughout the 4 h observation period. These changes were not accompanied or preceded by changes in plasma renin activity, angiotensin II or aldos terone. In this study patients were on a fixed diet; urine losses were not replaced isovolumetrically. After continu ous oral furosemide therapy during 8-10 days reciprocal changes between haemodynamic and hormone indices were observed. As the diuretic response diminished, cardiac output and pulmonary arterial pressure declined, whereas the renin-angiotensin system was activated. This suggests that during chronic therapy plasma renin activity and angiotensin II might counteract the vasodilatory effects of furosemide. However, there are some reports that are in disagreement with this hypothesis [18, 19] . In patients with severe congestive heart failure, intravenously administered furosemide caused an early fall in stroke volume index and a quick transient increase in the systemic vascular resis tance, a rise in mean arterial blood pressure (within 20 min AHF = acute heart failure; CHF = chronic heart failure; CO = cardiac output; i.v. = intravenously; MAP = mean arterial pressure; PAP = pulmonary arterial pressure; p.o. = orally; PWP = pulmonary wedge pressure; SVI = stroke volume index; SVR = systemic vascular resistance; SVI = stroke volume index; VC = venous capacitance.
o VO (1996) 988-997 AT II = angiotensin II; BP = blood pressure; FBF = forearm blood flow; i.v. = intravenously; NE = norepinephrin; PAP = pulmonary arterial pressure; PRA = plasma renin activity; PWP = pulmonary wedge pressure; SBP = systolic blood pressure; SVR = systemic vascular resistance; VC = venous capacitance.
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after injection), associated with an increase in plasma renin activity, norepinephrine and plasma arginine-vasopressin levels [18] . These results were strengthened by the out come of a study in spontaneously hypertensive rats [19] in which furosemide (3 mg/kg) caused an early fall in stroke volume and cardiac index. A decrease in mean arterial blood pressure was observed after a delay of 2 to 4 h, which was sustained for 6 to 8 h after injection. Total peripheral vascular resistance increased substantially and returned to baseline range within 24 h. The supposed mechanisms involved in the differences between the acute and chronic effects include an adaptation of baroreflex activity, a direct vasodilatory effect of diuretics, a de creased reactivity of the vascular system to pressor stimuli, a reduction of extracellular body fluid volume, and/or the production of endogenous vasodilator substances mediated by furosemide.
The dose-dependency of the vascular effects of furosemide was characterized in healthy volunteers by using dosages ranging from 5 to 80 mg [20] . Increases in venous capacitance were observed 5 min after i.v. adminis tration of 5 and 10 mg furosemide. Over the dose range 20-80 mg, no significant increases were observed. How ever, after 10 min venous responses showed significant increases in venous capacitance, equally for all dosages used. An oral dosage of 80 mg furosemide produced a rise in venous capacitance 15 min after administration and a decrease in forearm bloodflow 15-60 min after administra tion. A decrease in calf blood flow was observed within 15 min following administration of furosemide, regardless of salt balance or use of indomethacin [20] . This latter effect of furosemide was associated with a rise in plasma renin activity and was not observed in anephric patients [21] .
The role of the kidneys
In an attempt to elucidate the role of the kidneys in the haemodynamic effect of furosemide, vascular responses were studied in functionally anephric hypertensive patients [21] . In contrast to experiments in subjects with normal renal function, intravenously administered furosemide caused a significant increase in forearm blood flow of 55% within 15 min, whereas venous capacitance, weight hemat ocrit and plasma renin activity were unchanged (see Table  3 ). Possibly, this represents a direct vascular effect of furosemide, which becomes unmasked in the absence of counteracting mechanisms, such as the renin-angiotensin system, In another study, the effect of intravenously ad ministered furosemide on venous capacitance and calf blood flow was compared in healthy volunteers and anephric patients [22] . Venous capacitance increased in healthy volunteers, but not in anephric patients. Moreover, this effect of furosemide required a salt-retaining state and it could be blocked by the use of the cyclo-oxygenase blocker, indomethacin, suggesting an important role for renal prostaglandins in the systemic vascular effects of furosemide.
Furosemide (5 m g/kg) attenuated the vasoconstrictor responses of the mesenteric blood vessels in the rat to both exogenous angiotensin II and norepinephrine [23] . Acute bilateral nephrectomy or treatment with indomethacin (2 m g/kg i.v.) completely prevented this inhibitory effect. In a subsequent report the inhibitory effect of furosemide on the vasoconstrictor response to sympathetic nerve stimula tion was absent after chemical renal medullectomy [24] . The authors explained this effect by postulating that in the renal medulla non-prostanoid vasodilatory lipids are pro duced which mediate the vasodilatory effect of furosemide [25] . Intrarenal prostaglandins probably are involved in the release of such a lipid. Although substantial evidence of a direct vascular effect of furosemide is available from several in vitro experiments (see foregoing and Table 1 ), a coincidence of hormonal changes with the observed vascu lar effects was not considered.
The renin-angiotensin-aldosterone system
The release of renin is controlled by three mechanisms: the intrarenal baroreceptor, the sympathetic nervous sys tem and the macula densa receptor [26] . Results of some studies show a participation of prostaglandins in renin release [27] [28] [29] . It was demonstrated that prostaglandins mediate renin release in response to intrarenal baroreceptor stimulation [30] . On the other hand, renin release due to symthathetic nerve stimulation is prostaglandinindependent [31] . Micropuncture experiments in rats indi cate that renin release resulting from macula densa recep tor stimulation during sodium deprivation is prosta glandin-dependent [29] , whereas in dogs the macula densa mechanism of renin release could be blocked by inhibition of prostaglandin synthesis [32] . It is known from ex vivo experiments that furosemide exerts a direct stimulating effect on renin secretion [33] , In the isolated perfused rat kidney, furosemide-stimulated renin secretion did not re quire intact PGI2 synthesis [34] . The authors proposed that increased prostaglandin production and increase of renin release after furosemide administration is not causally related, but may be based on a common response to changes in sodium balance. In fact, prostaglandin synthesis could even be a counteracting mechanism participating in the vasoconstrictor action of angiotensin II [35] .
The importance of angiotensin II in the vascular effects of 5 mg intravenously administered furosemide was stud ied in healthy volunteers [36] . Captopril 50 mg abolished the acute increases in venous capacitance and attenuated the increase in forearm vascular resistance. The mecha nism suggested is that angiotensin II is formed secondarily to furosemide-stimulated renin release, and that the de crease in forearm blood flow is the result of the vasocon strictive effect of angiotensin II. Angiotensin II receptors are virtually absent in veins, so the net effect appears to be venodilation due to the angiotensin-induced release of vasodilatory prostaglandins from the kidney [36] . This view may not be entirely correct, as it has been demon strated that angiotensin II has a direct venoconstrictive effect on the human dorsal hand vein [37] .
To determine whether the vascular effects of furosemide are shared by bumetanide, another frequently used loop diuretic, the vascular and renal effects of equipotent dosages of furosemide and bumetanide were compared in healthy volunteers with moderate [38] and severe salt depletion [39] . In the case of moderate salt depletion, both furosemide (10 and 100 mg) and bumetanide (250 jmg and 250 mg) caused an increase in renal blood flow in both dosages. Changes in peripheral vascular responses did not differ from placebo. Both treatments led to an acute in crease in urinary prostaglandin metabolite excretion (which may be a reflection of an increased renal blood flow) and plasma renin activity (the latter not increased by bumetanide 250 jxg). Angiotensin II was increased signifi cantly 30 min after 100 mg furosemide and 2.5 mg bumetanide. Plasma norepinephrine was not influenced by any of the treatments [38] . In contrast with these observa tions was the vascular response to furosemide (10 and 20 mg) and bumetanide (250 and 500 jjtg) in marked salt depletion [39] . Significant reductions in forearm blood flow were observed after both furosemide dosages, but not after either of the bumetanide dosages. Both drugs had no significant influence on venous capacitance. Furosemide induced an increase in plasma renin activity, whereas bumetanide did not. The differences between furosemide and bumetanide with regard to acute arterial vasoconstric tive activity may be attributed to the ability of furosemide (and the disability of bumetanide) to stimulate acute renin release from the kidney.
The discrepancy between the results of this study [39] and that by Johnston et al. [38] with respect to vascular effects may be caused by differences in the degree of salt depletion. This is emphasized by others [17, 40] . There are no in vitro studies that compare the vascular effects of furosemide and bumetanide.
As illustrated in the foregoing paragraphs, the total body sodium content is an important factor in the modula tion of the indirect vascular response to furosemide. Ad ministration of a loop diuretic to a salt-depleted subject may further activate the renin-angiotensin system, causing a more pronounced arterial vasoconstriction.
Prostaglandins
In 1975 it was shown in dogs that pretreatment with the cyclo-oxygenase inhibitor indomethacin blocked the in crease in renal blood flow caused by furosemide [41] . Since then several studies have explored the role of prosta glandins in the natriuretic and vascular responses to furosemide [30, 34, 40, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . It is of importance to distin guish the effects of circulating prostaglandins of renal origin from prostaglandins produced in the local (extrarenal) vascular bed, since the furosemide-induced vascu lar effects may well be dependent on prostaglandins lo cally produced in the vessel wall. However, in in-vivo experiments it is difficult to study these two sources of prostaglandins separately.
The kidney releases PGI2, PGE2, PGF2a and throm boxane A 2 [42] . PGI2 and PGE2 possess important va sodilatory properties under conditions of prior vasocon striction. Prostaglandin-induced vasodilatation plays an im portant role in the maintenance of glomerular filtration and perfusion by dilatation of the afferent arteriole in a salt-de pleted state, when the renin-angiotensin system is acti vated [53] .
Furosemide has been shown to increase the urinary excretion of prostaglandin [38, 50, 52] . Whether this is caused by increased renal blood flow or by increased production of prostaglandins is unclear. On the other hand, reports on the effects of inhibition of prostaglandin synthe sis on furosemide-induced natriuresis are conflicting, prob ably due to variations in salt balance during the experi ments [42] .
In healthy volunteers PGI2 induced renin release and furosemide-induced renin release were associated with re nal PGI2 formation [54] . In a study performed in normotensive volunteers, indomethacin (75 mg) decreased both the peak urine flow rate and total sodium excretion within 1 h of a 30 mg i.v. furosemide dose, while an increase in renal plasma flow and glomerular filtration rate after furosemide was inhibited [48] , The increase in urinary excretion of PGE2 was abolished by indomethacin. The urinary excretion of a metabolite of systemic PGI2 was unaltered after furosemide injection. The authors stated that the early haemodynamic effects of furosemide depend on an increased synthesis of prostaglandins, particularly PGE2 and probably also PGI2. However, it is questionable whether the non-renal effects are a result of increased circulating prostaglandin levels [24, 43] . Arguments that underscore these doubts are: prostaglandins are very labile, are rapidly metabolized, and increased plasma levels of prostaglandins have never been measured after furosemide administration.
Although the studies mentioned above suggest that furosemide induces an increment in renal prostaglandin production, they do not clarify whether systemic prosta glandin synthesis-the local production in the extrarenal vasculature-is increased by furosemide. Mediation of the cardiovascular effects of furosemide by vascular products of arachidonate metabolism were studied in ex vivo experi ments using an isolated perfused canine lung lobe [47] . Furosemide decreased the mean pulmonary artery pressure. This direct arterial vasodilatory activity of furosemide was similar to that of PGI2 and could be inhibited with indo methacin, suggesting that furosemide induces a local pro- duction of PGI2 in resistance and/or capacitance vessels.
Recently, an in vitro study was published showing that furosemide in primary cultured bovine aortic endothelial cells stimulated the formation of endothelium-derived kinin, a potent stimulator of endothelial nitric oxide and PGI2 formation [43] . These experiments suggest that haemodynamic effects of furosemide are mediated by prostaglandins released from the local vasculature.
Conclusions
Although in the past 25 years much research has been done, the exact mechanism by which furosemide induces its vascular effects remains unclear. In Fig. 1 the mecha nisms involved in the vascular effects are shown. It seems clear that both direct and indirect mechanisms play a role. The venous vascular response to furosemide appears to be a direct effect, while the arterial response in vitro only occurs at supratherapeutic concentrations, and probably is mediated and modified by other factors like the degree of salt depletion, renin, angiotensin II and prostaglandins in vivo. The prostaglandins are either produced by the kid neys or by the endothelium, whereas the precise role of the endothelium has not yet been completely clarified.
Much attention has been paid to the arterial response, while the effects on the venous component have only been roughly monitored due to a lack of sensitive techniques to monitor local venous effects. However, especially in pa tients suffering from cardiac failure, the venous vasodila tion might be of importance in the observed acute benefi cial effects.
There are two methods available to study direct vascu lar effects in vivo. First, direct effects on resistance arteries in the human forearm can be studied with the perfused forearm technique. Using this method, direct vasoconstric tive or vasodilator effects on resistance arteries in the human forearm can be examined by drug administration into the brachial artery and venous occlusion plethysmographic recordings [55] . Second, with a linear variable differential transducer it is possible to measure direct venous vascular effects on a selected dorsal hand vein [56, 57] , With these methods it is possible to examine local vascular effects without provoking systemic counterregulatory effects. In a quest to explore the genuine direct vascular effects of loop diuretics in vivo, these methods provide the best options for future studies.
